Table 1.

Baseline characteristicsa

Placebo n = 27Losartan n = 26Spironolactone n = 27
Female, no.151314
Race, no.
    Black1087
    Hispanic121217
    Non-Hispanic white462
    Native American101
Age, yr49.3 (8.8)52.3 (9.1)51.7 (9.3)
Body mass index, kg/m232.3 (7.1)30.3 (5.4)33.7 (7.1)
Duration of diabetes, yr14.4 (9.6)17.0 (7.7)17.0 (9.1)
Diabetes type (type1/type 2), no.4/234/224/23
24-h ambulatory BP, mmHg
    Systolic138 (15)143 (15)135 (11)
    Diastolic75 (9)75 (9)71 (9)
Clinical BP, mmHg
    Systolic132 (18)136 (14)132 (16)
    Diastolic74 (9)72 (11)73 (10)
Prior history of myocardial infarction/CABG/PTCA322
UACR, mg/g917 [633–1329]897 [611–1316]1094 [758–1579]
Serum creatinine, mg/dl1.4 (0.7)1.7 (0.7)1.8 (0.9)
Normalized protein catabolic rate, g/kg/d0.97 (0.21)1.07 (0.26)0.91 (0.21)
Blood urea nitrogen, mg/dl30.5 (16.3)39.1 (18.6)43.4 (22.8)
Serum potassium, mEq/L4.5 (0.7)4.5 (0.4)4.5 (0.7)
Hemoglobin A1c, %8.1 (1.3)7.6 (1.3)7.4 (1.6)
Plasma C-reactive protein, mg/L3.6 [1.9–6.5]2.4 [1.4–4.2]3 [1.6–5.5]
Triglycerides, mg/dl183 [145–232]175 [136–225]191 [156–235]
Total cholesterol, mg/dl189 (49)198 (75)176 (44)
LDL cholesterol, mg/dl95 (38)100 (45)75 (29)
HDL cholesterol, mg/dl43 (10)46 (15)45 (11)
  • CABG, coronary artery bypass graft; PCTA, percutaneous transluminal coronary angioplasty.

  • aResults are presented as mean (SD) or geometric mean [95% CI].